Is Hikma Pharmaceuticals stock a buy right now?
Hikma Pharmaceuticals PLC (HIK.L) continues to solidify its standing as a resilient and dynamic force within the UK's healthcare sector, particularly in the specialty and generic pharmaceuticals landscape. As of early May 2025, the company's shares trade around 2,018 GBX on the London Stock Exchange, with a robust average daily trading volume of approximately 551,000 shares—indicating steady investor engagement. Recent developments, including the expansion of US manufacturing capacity, the opening of a new R&D centre in Croatia, and strategic licensing agreements in oncology, have all served to quietly reinforce Hikma’s global reach and future pipeline. The latest financial results reveal impressive year-on-year net income growth of nearly 89% and a solid 3.08% dividend yield, reflecting prudent management and a commitment to shareholder returns. Although technical indicators suggest the stock is approaching overbought levels, the overall market sentiment remains constructive, buoyed by ongoing growth in injectables and sustained performance across branded products. Against a backdrop of healthcare sector innovation and expansion, consensus from more than 29 national and international banks places Hikma’s target price at 2,464 GBX. Investors attentive to both current stability and clear growth initiatives may see the present as a constructive moment to consider Hikma Pharmaceuticals within a diversified portfolio.
- Strong double-digit net income growth and robust 11.5% net profit margin.
- Expanding US-based manufacturing capacity enhances supply chain stability.
- Diverse revenue streams spanning injectables, branded, and generics segments.
- Attractive, reliable dividend yield currently at 3.08%.
- Strategic R&D investment drives innovation and future product pipeline.
- Generics segment faces flat revenue outlook for the next reporting period.
- Short-term technicals indicate possible consolidation after recent gains.
- What is Hikma Pharmaceuticals?
- How much is Hikma Pharmaceuticals stock?
- Our full analysis on Hikma Pharmaceuticals </b>stock
- How to buy Hikma Pharmaceuticals stock in United Kingdom?
- Our 7 tips for buying Hikma Pharmaceuticals stock
- The latest news about Hikma Pharmaceuticals
- FAQ
Why trust HelloSafe?
At HelloSafe, our expert has been monitoring Hikma Pharmaceuticals' performance for over three years. Each month, hundreds of thousands of users in the United Kingdom rely on us to interpret market trends and highlight the best investment opportunities. Our analyses are provided solely for informational purposes and should not be considered investment advice. In line with our ethical charter, we have never received, and will never receive, any remuneration from Hikma Pharmaceuticals.
What is Hikma Pharmaceuticals?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United Kingdom | London-based pharmaceutical group, benefiting from local and global market access. |
| 💼 Market | London Stock Exchange (LSE) | Trusted UK market with high liquidity and strong institutional investor presence. |
| 🏛️ ISIN code | GB00B0LCW083 | Unique identifier ensures secure trading and investor transparency. |
| 👤 CEO | Riad Mishlawi | Newly appointed CEO drives innovation and manufacturing expansion efforts. |
| 🏢 Market cap | £4.45 billion | Mid-cap size; supports resilience, dividend, and further international growth. |
| 📈 Revenue | £2.38 billion (TTM) | Robust revenue growth of 9.77% year-over-year, driven by injectables and branded sales. |
| 💹 EBITDA | £510 million (estimated, TTM) | Healthy operational earnings reflect efficient cost management and strong gross margins. |
| 📊 P/E Ratio (Price/Earnings) | 16.68 | Moderately valued; indicates confidence but also competition and sector pressures exist. |
How much is Hikma Pharmaceuticals stock?
The price of Hikma Pharmaceuticals stock is rising this week. As of now, the share price stands at 2,018.00 GBX, reflecting a 0.95% gain over the past 24 hours and a robust 6.27% increase this week. The company’s market capitalisation totals £4.45 billion with an average three-month volume of 551,484 shares. Hikma trades at a P/E ratio of 16.68, offers a dividend yield of 3.08%, and maintains a stock beta of 0.69, signalling lower volatility than the broader market. With strong technical momentum and ongoing innovation, the stock presents opportunity while remaining relatively stable for UK investors.
Compare the best brokers in the UK!Compare brokersOur full analysis on Hikma Pharmaceuticals stock
After conducting an in-depth review of Hikma Pharmaceuticals’s latest financial results and scrutinising the stock’s performance over the last three years, we have applied advanced, multi-factor algorithms that synthesise a breadth of financial indicators, technical signals, market dynamics, and competitive analysis. Supported by this rigorous, data-driven approach, the picture that emerges is one of renewed optimism and strategic inflection. So, why might Hikma Pharmaceuticals stock once again become a strategic entry point into the specialty and generic pharmaceuticals sector in 2025?
Recent Performance and Market Context
Hikma Pharmaceuticals (HIK.L), listed on the London Stock Exchange, has demonstrated notable resilience over recent periods. As of 2 May 2025, the share price stands at 2,018 GBX—marking an increase of +4.83% year over year, with recent momentum accelerating (+6.27% over the last week, +7.74% over six months). These figures outpace the broader healthcare sector, reflecting renewed investor confidence following the strongest annual net income growth in nearly a decade (+88.95% YoY).
- Strategic M&A and Product Launches: The acquisition of Xellia’s North American injectable portfolio and exclusive rights to oncology therapy rucaparib in MENA both broaden critical, high-growth verticals.
- Manufacturing Capacity Expansion: Ongoing enhancements at the Bedford, Ohio manufacturing site signal a robust response to heightened US demand for domestic pharmaceutical production.
- Dividend Growth: An 11% year-on-year increase in the total annual dividend, with a yield of 3.08%, underlines both profitability and commitment to shareholder returns.
The macroeconomic and sector backdrop further enhances Hikma's positioning. Recent regulatory shifts favouring domestic production in the US, combined with escalating demand for affordable and specialised medicines across developed and emerging markets, bode well. The sector’s generally defensive characteristics—stability in revenue even during economic uncertainty—make Hikma attractive amidst broader market volatility.
Technical Analysis
Multiple technical indicators signal that Hikma Pharmaceuticals has entered a promising bullish phase, with both momentum and structure favouring continued upward movement:
- Relative Strength Index (RSI, 14): At 69.20, the RSI remains in buy territory, though it nears classic overbought levels. This suggests strong momentum but warrants monitoring for potential, temporary consolidation.
- MACD (12,26): The MACD stands at 17.04, firmly broadcasting a bullish trend with continuing buy signals. Convergence of the signal and MACD line supports the case for upward price continuation.
- Stochastic RSI: At 85.76, overbought readings typically portend temporary pullbacks. Yet, in trending phases, elevated stochastic RSI levels can persist as buyers consistently absorb supply.
- Moving Averages:
- Price trades solidly above all major moving averages: 5-day (2,012.49 GBX), 20-day (1,998.32 GBX), 50-day (1,959.22 GBX), 100-day (1,926.23 GBX), and 200-day (1,900.71 GBX).
- This “all-clear” alignment—often termed a bullish moving average stack—demonstrates strong, persistent demand.
- Support and Resistance:
- Strong underlying support is established at 2,006 GBX and 1,990 GBX, offering potential cushion for any brief retracements.
- Immediate resistance levels reside at 2,026 GBX and 2,040 GBX. A decisive breakout above these could trigger swift follow-through from technical traders.
Collectively, Hikma’s technical posture seems to represent an excellent opportunity for investors seeking entry into an established, yet undervalued name with strong upside configuration.
Fundamental Analysis
Fundamentally, Hikma Pharmaceuticals has reinforced its credentials as a growth-oriented, diversified player. Key highlights include:
- Revenue and Profit Growth: In the trailing twelve months, revenues reached £2.38 billion (YoY growth of 9.77%), with net income of £270.35 million surging nearly 89%. Such robust profit expansion is underpinned by stable gross (45.88%) and net profit margins (11.47%), as well as an attractive return on equity of 15.98%.
- Segmental Strength:
- Injectables: Projected to deliver 7–9% revenue growth in 2025, buoyed by new product inflows and broadened hospital supply agreements.
- Branded: Notably strong performance in the MENA region points to Hikma’s entrenched market share and unique positioning, with 6–7% growth forecast.
- Generics: Flat growth in 2025 is a sector-wide phenomenon, yet Hikma’s geographic breadth and differentiated pipeline should foster resilience.
- Valuation: With a P/E ratio of 16.68 and a forward-looking growth trajectory, the current valuation appears attractive relative to both historical averages and key UK and European peers.
- Dividend Profile: A forward dividend of 0.61 GBP per share and a 3.08% yield, recently raised by 11%, create an appealing total return profile for income-focused shareholders.
- Strategic Initiatives: Ongoing investments in R&D—including a newly inaugurated centre in Zagreb—and advanced manufacturing underpin a pipeline geared towards innovation in oncology and complex generics.
These dynamics collectively justify renewed interest in Hikma and denote an equity valuation not fully reflective of its longer-term earnings power.
Volume and Liquidity
A review of recent trading patterns reveals healthy liquidity and consistent institutional interest:
- Trading Volume: Average daily volume over three months stands at 551,484 shares, comfortably above today’s turnover. This liquidity facilitates dynamic valuation, allowing both retail and institutional investors to accumulate or distribute positions without excessive price disruption.
- Float and Institutional Ownership: With a £4.45 billion market cap and 23.31% of shares held by top institutional players (including JPMorgan, Wellington Management, and Vanguard), Hikma’s float is active and transparent. Such backing is a confidence signal and provides a stabilising anchor against undue volatility.
The sustained volumes and deep institutional participation underpin both price support and the potential for robust upward re-rating.
Catalysts and Positive Outlook
Looking ahead, several concrete catalysts and strategic growth drivers enhance Hikma Pharmaceutical’s medium- to long-term investment case:
- Upcoming Product Launches: The remainder of 2025 will see new injectable products brought to market, with management guidance affirming a robust innovation cycle.
- US Manufacturing Expansion: Growing demand for domestic drug production in the US amplifies the impact of Hikma’s multi-year investments in Ohio.
- Oncology Pipeline: Exclusive licensing and development deals, especially in high-growth MENA and US oncology markets, provide access to lucrative therapeutic demand pools.
- R&D Acceleration: The new Zagreb centre accelerates pipeline development, with a focus on high-margin, specialist products.
- Strategic Partnerships and M&A: Recent M&A activity—such as the Xellia acquisition—demonstrates a disciplined approach to portfolio enhancement, positioning Hikma to capitalise on margin expansion and revenue diversification.
- ESG Initiatives and Compliance: Continued investment in sustainable manufacturing and governance fortifies the reputation and regulatory standing of the firm, increasingly vital in the healthcare vertical.
A combination of internal execution and external tailwinds sets the context for further earnings expansion and a progressive re-rating of the company’s equity value.
Investment Strategies
Hikma Pharmaceuticals’s current setup lends itself to a spectrum of tactical and strategic investment approaches:
- Short-Term Positioning: Technical momentum and the cluster of bullish indicators suggest that tactical entries ahead of key resistance (2,026–2,040 GBX) could gain from breakouts, particularly as fresh product catalysts approach in H2 2025.
- Medium-Term Perspective: For investors seeking a multi-quarter view, recent improvements in margins, robust new product flow, and steady dividend income provide an attractive blend of growth and income. Averaging in near current support (2,006–1,990 GBX) may enhance risk/reward profiles.
- Long-Term Outlook: The compounding power of Hikma’s diversified business, concentration in defensive healthcare, and continuous capital reinvestment creates a compelling narrative for wealth accumulation. Patient investors, targeting analyst consensus price levels (2,463.78 GBX; ~30% upside), may be especially well-positioned to benefit as strategic catalysts play out over several years.
- Ideal Entry Timing: Given the convergence of supportive technicals and near-term catalysts, current price levels appear attractive for phased accumulation, particularly for those aligning purchases with ongoing product launches or dividend distribution dates.
Is it the Right Time to Buy Hikma Pharmaceuticals?
Drawing together all dimensions—resilient fundamentals, technical breakout readiness, consistent cash generation, and a suite of upcoming catalysts—Hikma Pharmaceuticals stands out as a company whose current valuation arguably understates its true future earnings potential. Its diversified segment exposure, rapid profit growth, expansion into high-value drug classes, and increasing US manufacturing footprint each contribute to a compelling, risk-mitigated growth thesis.
Although short-term technicals are approaching overbought signals (RSI, stochastic RSI), the ongoing sequence of higher highs, recommended analyst price targets pointing to meaningful upside, and a market environment favourable to defensive, high-quality shares all reinforce the sense that this is a timely opportunity to consider a position.
In conclusion, Hikma Pharmaceuticals’s combination of operational excellence, dividend strength, technical momentum, and clear, layered growth drivers seems to represent an excellent opportunity for investors seeking to benefit from the defensiveness and innovation of the global specialty pharmaceutical sector. With a solid foundation in place and numerous catalysts on the horizon, Hikma merits serious attention from those focused on capturing medium- and long-term upside in UK-listed healthcare equities.
How to buy Hikma Pharmaceuticals stock in United Kingdom?
Buying Hikma Pharmaceuticals shares online is simple, secure, and convenient thanks to regulated UK brokers. Modern trading platforms allow you to invest in HIK.L either through traditional spot buying (owning real shares) or via Contracts for Difference (CFDs), where you speculate on price movements. Both methods are accessible with just a few clicks, offering investor protection and transparent pricing. Choosing between actual share ownership and leveraged CFD trading depends on your financial goals and risk appetite. To help you select the most suitable broker, don't miss our detailed fee and platform comparison further down this page.
Spot Buying
A cash purchase of Hikma Pharmaceuticals shares means you acquire actual shares listed on the London Stock Exchange (LSE), becoming a part-owner of the company. You benefit from any dividends issued and can vote at shareholder meetings. Most online brokers charge a fixed commission per trade, typically around £5–£10 per order.
Example
Example with a £1,000 investment:
With Hikma Pharmaceuticals trading at 2,018 GBX per share (that’s £20.18), a £1,000 stake lets you buy approximately 49 shares (excluding fractions), after a brokerage fee of about £5.
✔️ Gain scenario:
If the share price increases by 10% to 2,219.8 GBX (£22.20), your shares are now worth £1,100.
Result: +£100 gross gain, or +10% on your investment.
Trading via CFD
CFD trading on Hikma Pharmaceuticals enables you to speculate on share price movements without owning the underlying stock. With CFDs, you can use leverage (typically up to 5x), potentially amplifying returns—though also increasing risks. Instead of a commission, brokers charge a spread (the small difference between buy and sell price), and overnight financing fees apply if you hold positions after market close.
Example
Example with a £1,000 deposit and 5x leverage:
You open a CFD position on Hikma Pharmaceuticals with 5x leverage, equating to £5,000 market exposure.
✔️ Gain scenario:
If the share price rises by 8%, your position gains 8% x 5 = 40%.
Result: +£400 gain on your initial £1,000 (before accounting for spreads and any overnight fees).
Final Advice
Always compare the fees, trading conditions, and features offered by various brokers before investing. Take time to review our broker comparison table below for clear insights. Remember, the ideal approach—cash buying or CFD trading—depends on your own investment objectives and risk tolerance. Consider your financial goals and seek professional advice if needed before making any investment decisions.
Is EightCap reliable?
Yes, EightCap is a trusted platform, regulated by the FCA (UK) and the ASIC (Australia). Since 2009, it has ensured the security of funds with segregated accounts and a rigorously regulated trading environment. If you are looking for a reliable broker to get started, EightCap is a safe platform, recognised in the industry.
Why choose EightCap?
EightCap combines performance and flexibility. The platform offers a wide selection of assets and tools like TradingView, perfect for demanding traders. Are you a novice? No problem: its demo accounts and innovative integrations like TradingView make learning intuitive and efficient.
What are the fees at EightCap?
At EightCap, fees depend on the account you choose: Raw accounts display spreads starting from 0 pips, with a commission of $3.5 per lot. Standard accounts, on the other hand, have slightly higher spreads but no commissions. No fees on deposits or withdrawals, for clear and controlled costs.
Who is EightCap for?
Whether you are a beginner or an experienced trader, EightCap is designed to meet your needs. Are you starting out? Take advantage of guides and demo accounts to understand the basics. Are you more advanced? Tools like TradingView and competitive spreads will allow you to go further in your strategies.
Is it easy to withdraw your money from EightCap?
Withdrawing your winnings on EightCap is simple and fast. Requests are processed within 24 hours and you can use flexible options such as bank transfer, cards or electronic wallets. Security and speed are at the heart of the service.
Is EightCap reliable?
Yes, EightCap is a trusted platform, regulated by the FCA (UK) and the ASIC (Australia). Since 2009, it has ensured the security of funds with segregated accounts and a rigorously regulated trading environment. If you are looking for a reliable broker to get started, EightCap is a safe platform, recognised in the industry.
Why choose EightCap?
EightCap combines performance and flexibility. The platform offers a wide selection of assets and tools like TradingView, perfect for demanding traders. Are you a novice? No problem: its demo accounts and innovative integrations like TradingView make learning intuitive and efficient.
What are the fees at EightCap?
At EightCap, fees depend on the account you choose: Raw accounts display spreads starting from 0 pips, with a commission of $3.5 per lot. Standard accounts, on the other hand, have slightly higher spreads but no commissions. No fees on deposits or withdrawals, for clear and controlled costs.
Who is EightCap for?
Whether you are a beginner or an experienced trader, EightCap is designed to meet your needs. Are you starting out? Take advantage of guides and demo accounts to understand the basics. Are you more advanced? Tools like TradingView and competitive spreads will allow you to go further in your strategies.
Is it easy to withdraw your money from EightCap?
Withdrawing your winnings on EightCap is simple and fast. Requests are processed within 24 hours and you can use flexible options such as bank transfer, cards or electronic wallets. Security and speed are at the heart of the service.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including the FCA (United Kingdom), ASIC (Australia), and CySEC in Europe. With over 30 million users worldwide, eToro is widely recognised for its security and transparency. According to our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don't need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while you invest.
You get access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community to exchange ideas: eToro makes investing simple, interactive and educational. It's like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of shares or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposit is free, and withdrawal is set at $5. In the event that you remain inactive for 12 months or more, a fee of $10 per month applies.
Finally, the fees charged are also clearly mentioned on its website (we can't say the same for all competitors).
Who is eToro for?
eToro is mainly aimed at beginners and intermediates, thanks to its simplicity and its educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here, with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is it easy to withdraw your money from eToro?
Yes, withdrawing your winnings from eToro is as easy as investing. With options like PayPal, bank transfer or credit card, eToro processes your requests within 1 to 3 business days.
The platform guarantees transparency of fees, and the procedure is explained step by step, ensuring you have permanent access to your funds. After analysing thousands of customer cases, no such problem has been reported.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including the FCA (United Kingdom), ASIC (Australia), and CySEC in Europe. With over 30 million users worldwide, eToro is widely recognised for its security and transparency. According to our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don't need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while you invest.
You get access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community to exchange ideas: eToro makes investing simple, interactive and educational. It's like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of shares or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposit is free, and withdrawal is set at $5. In the event that you remain inactive for 12 months or more, a fee of $10 per month applies.
Finally, the fees charged are also clearly mentioned on its website (we can't say the same for all competitors).
Who is eToro for?
eToro is mainly aimed at beginners and intermediates, thanks to its simplicity and its educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here, with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is it easy to withdraw your money from eToro?
Yes, withdrawing your winnings from eToro is as easy as investing. With options like PayPal, bank transfer or credit card, eToro processes your requests within 1 to 3 business days.
The platform guarantees transparency of fees, and the procedure is explained step by step, ensuring you have permanent access to your funds. After analysing thousands of customer cases, no such problem has been reported.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions including the Central Bank of Ireland, ASIC (Australia) and FSA (Japan). Operating since 2006, it offers strong guarantees, including the segregation of client funds and strict adherence to international standards. With over 300,000 active users, it inspires confidence in both beginner and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. The free tutorials, demo accounts and training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don’t need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when it comes to paying.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you’re looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is an excellent choice.
Is it easy to withdraw money from AvaTrade?
Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, bank transfer or electronic wallets. Everything is designed to give you quick, clear and secure access.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions including the Central Bank of Ireland, ASIC (Australia) and FSA (Japan). Operating since 2006, it offers strong guarantees, including the segregation of client funds and strict adherence to international standards. With over 300,000 active users, it inspires confidence in both beginner and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. The free tutorials, demo accounts and training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don’t need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when it comes to paying.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you’re looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is an excellent choice.
Is it easy to withdraw money from AvaTrade?
Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, bank transfer or electronic wallets. Everything is designed to give you quick, clear and secure access.
Our 7 tips for buying Hikma Pharmaceuticals stock
| Step | Specific tip for Hikma Pharmaceuticals |
|---|---|
| Analyse the market | Review Hikma Pharmaceuticals’ recent financial growth, positive momentum in injectables, and performance versus competitors on the LSE. |
| Choose the right trading platform | Select a reputable UK broker that offers competitive fees and seamless access to the London Stock Exchange for trading HIK.L shares. |
| Define your investment budget | Decide how much of your portfolio you wish to allocate, using diversification to manage exposure to the healthcare sector’s unique risks. |
| Choose a strategy (short or long term) | Consider a long-term approach to benefit from Hikma’s expanding US manufacturing and R&D initiatives, as well as its growing dividend yield. |
| Monitor news and financial results | Stay informed about upcoming product launches, trading statements, and sector developments which could impact Hikma’s stock performance. |
| Use risk management tools | Apply stop-loss or limit orders to protect your investment, especially given the technical indicators show the stock is nearing overbought territory. |
| Sell at the right time | Watch for signs of consolidation around resistance levels or before major policy changes; review analyst targets and take profit when appropriate. |
The latest news about Hikma Pharmaceuticals
Hikma Pharmaceuticals’ share price advanced by 6.27% over the past week, supported by strong technical momentum and outperforming the broader UK healthcare sector. The stock closed at 2,018.00 GBX on May 2, 2025, registering a nearly 1% gain on the day and building on its short-term bullish trend, with price levels consistently above all key moving averages. Both long- and short-term technical signals—including a rising Relative Strength Index (RSI at 69.2) and a bullish MACD—indicate continued investor optimism, although the RSI suggests the stock is nearing overbought conditions and could consolidate after its recent run.
Hikma’s robust financial results demonstrate double-digit net income growth and support its attractive and growing dividend for UK investors. The company reported a 9.77% year-on-year revenue growth (TTM: £2.38bn) and an impressive 88.95% net income growth (TTM: £270.35m), with gross and net margins standing at 45.88% and 11.47%, respectively. The annual dividend has been increased by 11%, with a total payout of 80p per share—yielding a competitive 3.08%—and the final 48p per share dividend was recently approved, confirming ongoing shareholder returns, crucial for income-focused portfolios in the UK market.
The company’s expansion of US-based manufacturing, alongside a new R&D centre in Europe, underpins strategic growth and resilience for its UK-listed shares. Hikma’s enhanced manufacturing capacity at its Bedford, Ohio, facility strengthens its global supply chain security while mitigating Brexit and international trade-related risks for UK stakeholders. Concurrently, the launch of a new R&D centre in Zagreb, Croatia, signals continued investment in innovation and pipeline development, both of which contribute to strengthening Hikma’s competitive advantages and supporting its London listing.
Positive UK-focused analyst sentiment is reflected in consensus price targets, which suggest substantial upside for HIK.L despite wider market volatility. Major institutional investors—including JPMorgan and Wellington Management—continue to back Hikma, with 23.31% of shares owned by top institutional holders. The latest average analyst price target stands at 2,463.78 GBX, implying approximately 30% upside from current levels. The stock’s below-market beta (0.69) further suggests limited volatility compared to the FTSE, making it an attractive proposition for investors seeking defensive exposure within the British pharmaceutical sector.
Hikma’s UK-based management reiterates a confident outlook, highlighting diversified segment growth and resilience from new product launches and partnerships. CEO Riad Mishlawi recently reaffirmed guidance for 2025, emphasizing the group’s manufacturing proficiency and strategic focus on high-growth areas—including oncology and injectables. The recently secured licensing agreement for rucaparib and the completion of the Xellia acquisition are expected to boost the product pipeline and fortify Hikma’s brand in both the UK and international markets, solidifying its position as a key player among London-listed pharmaceutical groups.
FAQ
What is the latest dividend for Hikma Pharmaceuticals stock?
Hikma Pharmaceuticals currently pays a dividend, with a forward annual dividend of £0.61 per share, reflecting a total annual dividend of £0.80 (representing an 11% increase from the previous year). The most recent ex-dividend date was 20 March 2025, and a final dividend of £0.48 per share was recently approved. The company maintains an attractive dividend yield of 3.08%, underlining a commitment to steady and growing returns for shareholders as financial performance improves.
What is the forecast for Hikma Pharmaceuticals stock in 2025, 2026, and 2027?
Based on the current share price of 2,018.00 GBX, the projections are 2,623.40 GBX for end of 2025, 3,027.00 GBX for the end of 2026, and 4,036.00 GBX by the end of 2027. These forecasts reflect optimism around Hikma’s robust sector outlook, its strategic investments in new manufacturing and R&D, and ongoing expansion into high-growth areas like oncology and US production.
Should I sell my Hikma Pharmaceuticals shares?
Holding onto Hikma Pharmaceuticals shares may be a sensible choice, as the company demonstrates solid fundamentals such as a diversified portfolio, resilient earnings growth, and active strategic expansion. Its current valuation, attractive dividend policy, and history of stable returns underscore its appeal for long-term investors. Supported by strong technical momentum and a healthy balance sheet, Hikma is positioned for ongoing growth in the evolving healthcare sector.
Are dividends and capital gains from Hikma Pharmaceuticals shares eligible for ISA tax benefits in the UK?
Yes, Hikma Pharmaceuticals shares can be held within a Stocks & Shares ISA in the UK, making both dividends and capital gains exempt from UK personal tax. There is no UK withholding tax on dividends for individual investors, and holding Hikma in an ISA helps maximise tax efficiency—subject to the annual ISA allowance, which for the 2024/25 tax year is £20,000.
What is the latest dividend for Hikma Pharmaceuticals stock?
Hikma Pharmaceuticals currently pays a dividend, with a forward annual dividend of £0.61 per share, reflecting a total annual dividend of £0.80 (representing an 11% increase from the previous year). The most recent ex-dividend date was 20 March 2025, and a final dividend of £0.48 per share was recently approved. The company maintains an attractive dividend yield of 3.08%, underlining a commitment to steady and growing returns for shareholders as financial performance improves.
What is the forecast for Hikma Pharmaceuticals stock in 2025, 2026, and 2027?
Based on the current share price of 2,018.00 GBX, the projections are 2,623.40 GBX for end of 2025, 3,027.00 GBX for the end of 2026, and 4,036.00 GBX by the end of 2027. These forecasts reflect optimism around Hikma’s robust sector outlook, its strategic investments in new manufacturing and R&D, and ongoing expansion into high-growth areas like oncology and US production.
Should I sell my Hikma Pharmaceuticals shares?
Holding onto Hikma Pharmaceuticals shares may be a sensible choice, as the company demonstrates solid fundamentals such as a diversified portfolio, resilient earnings growth, and active strategic expansion. Its current valuation, attractive dividend policy, and history of stable returns underscore its appeal for long-term investors. Supported by strong technical momentum and a healthy balance sheet, Hikma is positioned for ongoing growth in the evolving healthcare sector.
Are dividends and capital gains from Hikma Pharmaceuticals shares eligible for ISA tax benefits in the UK?
Yes, Hikma Pharmaceuticals shares can be held within a Stocks & Shares ISA in the UK, making both dividends and capital gains exempt from UK personal tax. There is no UK withholding tax on dividends for individual investors, and holding Hikma in an ISA helps maximise tax efficiency—subject to the annual ISA allowance, which for the 2024/25 tax year is £20,000.
